|Bid||6.25 x 1800|
|Ask||7.99 x 1800|
|Day's range||7.41 - 7.99|
|52-week range||6.51 - 23.85|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shares of Omeros (NASDAQ: OMER), a biopharmaceutical company, are falling today after the company made a disclosure regarding narsoplimab, an experimental treatment to address side effects of stem cell transplants. Omeros has just one revenue stream at the moment, Omidria, an expensive eye-drop solution that gets added to the bill when Medicare patients go under the knife for lens replacements and cataract removals.
Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.
Shares of Omeros Corporation (NASDAQ: OMER) are down 12.2% since Monday. Omeros didn't have any big news that would have affected its stock price this month. Its last real news was its second-quarter earnings report that came out on Aug. 9, which showed the biotech company reporting $28.8 million of revenue, up 37% year over year, and a net income loss of $28.6 million, compared to a loss of $35.1 million in the same period in 2020.